Suboptimal linkage to specialists and access to direct-acting anti-virals are the leading barriers to treatment.

However, data are limited.

Dr Kanwal and colleagues from Texas, USA determined predictors of follow-up, receipt of direct-acting anti-virals, and reasons for the lack thereof.

The research team used clinical data from retrospective cohort of HCV-infected patients with previously established HCV care in the US Department of Veterans Affairs to examine predictors of follow-up in HCV clinics and direct-acting anti-viral treatment.

The researchers then conducted a structured review of medical charts of HCV patients to determine reasons for lack of follow-up and treatment.

28% received direct-acting anti-virals

Alimentary Pharmacology & Therapeutics

The team identified 84 221 veterans who were previously seen in HCV clinics during the pre-direct-acting anti-virals era.

Of these, 56% were followed-up in HCV specialty clinics, 29% of whom received direct-acting anti-virals.